26 Results for "

cIAP-2

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "cIAP-2" in MCE Product Catalog:

  • Isoforms Recommended:
44
44 Publications Verification
Cat. No.: HY-16591
CAS No.: 1260251-31-7
Synonyms: TL32711
Target:  

IAP Apoptosis HIV

Research Areas:  

Cancer

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
16
16 Cited Publications
Cat. No.: HY-12600
CAS No.: 1258392-53-8
Purity:  98.75%
Target:  

IAP Apoptosis

Research Areas:  

Cancer

AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis .
16
16 Cited Publications
Cat. No.: HY-110346
CAS No.: 1883545-51-4
Target:  

IAP Apoptosis

Research Areas:  

Cancer

AZD5582 dihydrochloride is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis .
14
14 Cited Publications
Cat. No.: HY-13638
CAS No.: 873652-48-3
Purity:  99.70%
Target:  

IAP

Research Areas:  

Cancer

GDC-0152 is a potent IAPs inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of ML-IAP with Ki values of 28 nM, 17 nM, 43 nM and 14 nM, respectively.
12
12 Cited Publications
Cat. No.: HY-15454
CAS No.: 1071992-99-8
Purity:  99.91%
Synonyms: AT-406; Debio 1143; SM-406
Target:  

IAP Apoptosis

Research Areas:  

Cancer

Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively.
12
12 Cited Publications
Cat. No.: HY-13208
CAS No.: 1071992-57-8
Purity:  98.01%
Synonyms: AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride
Target:  

IAP Apoptosis

Research Areas:  

Cancer

Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors [2].
3
3 Cited Publications
Cat. No.: HY-N6064
CAS No.: 66663-91-0
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis
1
1 Cited Publications
Cat. No.: HY-N0732
CAS No.: 37905-08-1
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis [2] .
Cat. No.: HY-125593
CAS No.: 1570231-89-8
Purity:  99.36%
Synonyms: APG-1387
Target:  

IAP Apoptosis

Research Areas:  

Cancer

Dasminapant (APG-1387), a bivalent SMAC mimetic and an IAP antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma [2] .
Cat. No.: HY-111875
CAS No.: 2095244-54-3
Purity:  99.68%
Research Areas:  

Cancer

SNIPER(BRD)-1 is a SNIPER degrader of BRD4, cIAP1 and XIAP. SNIPER(BRD)-1 has IC50 values of 6.8 nM, 17 nM and 49 nM for cIAP1, cIAP2 and XIAP, respectively. SNIPER(BRD)-1 can be used for cancer research .
Cat. No.: HY-124181
CAS No.: 1562375-46-5
Purity:  98.71%
Target:  

IAP Apoptosis

Research Areas:  

Cancer

SM-1295 is an inhibitor of apoptosis protein (IAP) antagonist, with Kd values of 3077 nM, 3.2 nM and 9.5 nM for XIAP-BIR3, c-IAP1-BIR3 and c-IAP2-BIR3, respectively [2].
Cat. No.: HY-149924
CAS No.: 3033993-13-1
Purity:  95.87%
Target:  

PROTACs IAP

Research Areas:  

Cancer

CST626 (Compound 9) is a pan-IAP degrader PROTAC. CST626 degrades XIAP, cIAP1 and cIAP2 with DC50s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively .
Cat. No.: HY-151966
CAS No.: 3037417-26-5
Purity:  99.49%
Research Areas:  

Cancer

TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 activates Caspase 3/7, and promotes cancer cells apoptosis via IAP degradation. TD1092 inhibits TNFα mediated NF-κB pathway and reduces the phosphorylation of IKK, IkBα, p65, and p38. TD1092 can act as PROTAC, and is used for cancer research .
Cat. No.: HY-155019
CAS No.: 2941243-62-3
Target:  

IAP

Research Areas:  

Cancer

Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 128 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 24.9 nM, 19.3 nM, and 10.3 nM, respectively .
Cat. No.: HY-155018
CAS No.: 2410953-19-2
Target:  

IAP

Research Areas:  

Cancer

Anticancer agent 127 (142D6) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 127 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 12 nM, 14 nM, and 9 nM, respectively. Anticancer agent 127 has anticancer effects .
Cat. No.: HY-111874
CAS No.: 2222354-29-0
Target:  

SNIPERs Bcr-Abl

Research Areas:  

Cancer

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively .
Cat. No.: HY-111886
Target:  

SNIPERs IAP

Research Areas:  

Cancer

KHS108-MV1 is a conjugate of KHS108 and MV1. KHS108 is a ligand for TACC3. MV1 is an IAP antagonist that binds to cIAP1, cIAP2, and XIAP. KHS108-MV1 can be used in the research of breast cancer and fibrosarcoma .
Cat. No.: HY-N0732R
CAS No.: 37905-08-1
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis [2] .
Cat. No.: HY-RS01511
Research Areas:  

Others

Birc3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Birc3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS01510
Research Areas:  

Others

BIRC3 Human Pre-designed siRNA Set A contains three designed siRNAs for BIRC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.